No standard therapy with sufficient efficacy is available to treat this disease or it is not tolerated. By using experimental therapy, there is a reasonable prospect of improving the arrhythmia with few side effects.
Aim of the study
The aim of the study is to define the minimum required dose of stereotactic radiotherapy needed to successfully treat recurrent sustained arrhythmias in the form of ventricular tachycardia without the occurrence of relevant side effects.
Who can take part?
Patients with recurrent persistent cardiac arrhythmias
Procedure
All patients receive radiotherapy and are treated according to the same therapy protocol with regard to imaging and recording of side effects. The radiation dose is adjusted over the course of the study depending on the tolerability of the treatments. This means that not all patients are treated with the same dose. The treatment of the individual participant will be completed after a total of 24 months, just as with the standard treatment and close 2-year follow-up.
Compensation
None
Original study name
Dose Escalation for Stereotactic Cardiac Radiation Therapy of Recurrent Ventricular Tachyarrhythmia - a Multi-Center, Phase II Clinical Trial
BASEC number
2022-00262
Financial support from
University of Zurich